astrazeneca earnings forecast

AZN - AstraZeneca PLC Forecast - CNNMoney.com AstraZeneca starts to make modest profit from COVID-19 vaccine AstraZeneca banking on new orders as its COVID-19 vaccine ... astrazeneca: AstraZeneca starts to make modest profit from ... That translates to 18-24% growth in earnings . It has a portfolio of . Strong earnings forecasts, miners lift FTSE 100 to 3-week ... Astrazeneca PLC is expected* to report earnings on 11/12/2021 before market open. AstraZeneca plc (AZN) Stock Price & News - Google Finance AstraZeneca Stock Gains As Q2 Earnings Beat Forecasts, Clocks $894M In COVID-19 Vaccine Sales Guidance: AstraZeneca reiterated its full-year outlook for total revenue increasing by a low-teens percentage, and core earnings per share rising to $5.00 from $4.00, all at constant exchange rates. Q4 2019. A . Forecasts of 15 analysts expect earnings of $1.11 per share compared to earnings of $0.890 per share from the same quarter last . in the spotlight: astrazeneca The British-Swedish pharmaceutical giant AstraZeneca is expected to report earnings per share of GBP 92.54 in the third quarter on revenue of GBP 7.04 billion. According to Zacks Investment Research, based on 4 . The stock's 52-week trading range is $46.48 to $60.93. AstraZeneca said a profit boost from the vaccine in the fourth quarter would make up for costs related to its antibody cocktail for preventing and treating COVID-19, as it stuck with its earnings forecast for the year. AstraZeneca Plc Chief Executive Officer Pascal Soriot speaks to Bloomberg after the U.K. drugmaker raised its annual sales forecast, helped by demand for its roster of new cancer drugs. Additionally, P&S . AstraZeneca has reported 'solid' first quarter results, as sales of its COVID-19 vaccine take off and the company's oncology drugs deliver strong growth. The current consensus suggests it will be toward the lower end of that range and rise by 7.9% to $26.32 billion. Investors in AstraZeneca PLC had a good week, as its shares rose 9.1% to close at UK£84.73 following the release of its third-quarter results.Revenues were in line with forecasts, at US$6.6b, although statutory earnings per share came in 13% below what the analysts expected, at US$0.49 per share. AstraZeneca said a profit boost from the vaccine in the fourth quarter would make up for costs related to its antibody cocktail for preventing and treating COVID-19, as it stuck with its earnings . British American Tobacco gained 1.9% after reiterating its full-year profit and sales forecasts, as more people switched to its Vuse vaping and Velo oral nicotine products. AstraZeneca did not change its earnings guidance for the full year, still expecting core earnings per share to between $5.05 and $5.40. Heavyweight drugmaker AstraZeneca declined 1.7% after brokerage Jefferies downgraded the stock saying its earnings per share is set to decline to single-digit growth beyond 2026. AstraZeneca PLC (NASDAQ:AZN) traded at $57.37 at last check on Wednesday, December 22, made an upward move of 0.75% on its previous day's price. (RTTNews) - AstraZeneca (AZN.L, AZN) said, according to a study performed independently by investigators at the University of Oxford, the company's Vaxzevria significantly boosted levels of . MISSISSAUGA, ON, Dec. 3, 2021 /CNW/ - AstraZeneca Canada, a leading innovation-driven biopharmaceutical company, has been selected for the eighth consecutive year as one of Greater Toronto's Top . AstraZeneca said its earnings will fall by less than expected this year helped by the delayed launch of a rival's copy of one of the British health-care group's best-selling drugs, the . AstraZeneca's COVID-19 vaccine made a small contribution to earnings in the third quarter and it expects the shot to move to "modest profitability" on new . Total revenue is expected to grow by a mid-to-high twenties . Analysts have reduced this quarter's expectations by -0.7% for EPS from 1.15 per share to 1.14 per share over the last 12 months. The one listed on the U.S. exchange . AstraZeneca's third-quarter results showed its COVID-19 vaccine contributed one cent to core earnings per share of $1.08, a rise of 14 per cent . The department store chain Thursday also reported much better-than-expected fiscal third-quarter earnings. AstraZeneca said the vaccine added $0.01 to earnings per share in the quarter, but that it lost $0.03 per share from the development since the start of 2021. "In general, AstraZeneca continues to recognise the heightened risks and uncertainties from the effects of COVID-19," the company said. FDA Approves TEZSPIRE™ (tezepelumab-ekko), AstraZeneca and Amgen's First-in-Class Treatment for Severe Asthma The brand name TEZSPIRE™ was developed in partnership with Brand Institute, the . Adam O'Dell Is Smashing the Market 3-to-1 and Picking Huge Winners for Fun…. The stock's multiple based on expected 2021 earnings is 37. Analysts, on average, had forecast sales in the quarter of $7.92bn and earnings of $1.79/share, according to Thomson Reuters I/B/E/S. related to: azn stock forecast. Revenue also beat estimates. EPS Forecast Trend. Sell-off revenue of $562 million—which topped consensus by $67 million and made up 10% of AZ's $5.41 billion top-line haul—pushed (PDF) core earnings to 99 . 5 things to know before the stock market opens Thursday. Strong earnings forecasts, miners lift FTSE 100 to near 3-week highs . London's FTSE 100 slipped on Tuesday, weighed down by weaker shares of AstraZeneca and heavyweight consumer staples stocks, although upbeat earnings updates from Vodafone and spirits maker Diageo . The commodity-heavy FTSE 100 ended 1.5% higher with base metal miners leading gains as copper prices were boosted by monetary policy easing in top consumer China. AstraZeneca kept its full-year forecast unchanged for a low to mid single-digit decline in revenue and core earnings per share, though it said core EPS would gain a booster of the same magnitude . Today, I'm looking at the earnings per share forecasts for AstraZeneca (LSE: AZN.L) (NYSE: AZN), the FTSE 100 pharmaceutical group. Quarterly sales rose 19% to $5.72 billion at constant currency, above analysts' consensus of $5.45 billion. Get the latest AstraZeneca ADR earnings report, revenues as well as upcoming AZN earnings dates, historical financial reports, news, analysis & more. In the quarter ending September 30 . AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. "In general, AstraZeneca continues to recognise the heightened risks and uncertainties from the effects of COVID-19," the company said. AstraZeneca stock trades at 55.4 times expected 2021 EPS, 46.0 times estimated 2022 earnings and 38.9 times estimated 2023 earnings. earnings-and-revenue-growth. Looking at the stock we see that its previous close was $56.94 and the beta (5Y monthly) reads 0.15 with the day's price range being $56.51 - $57.20 . (Reuters) -London's FTSE 100 slipped on Tuesday, weighed down by weaker shares of AstraZeneca and heavyweight consumer staples stocks, although upbeat earnings updates from Vodafone and spirits . Dec 21 (Reuters) - Oxford University and AstraZeneca Plc AZN.L have begun work to produce an Omicron-targeted version of their coronavirus vaccine, the Financial Times reported on Tuesday. AstraZeneca, which is listed on the London Stock Exchange, said it expects revenue growth of a "low-teens percentage" in 2021. AstraZeneca broke below its uptrend after posting Q3 results. - The companies . Transgene (TRGNF) announces that AstraZeneca (AZN) has exercised its first license option for an Invir.IO oncolytic virus ((OV)) developed from their on-going collaboration.The exercise. London - AstraZeneca raised its sales and earnings forecasts for the year on Thursday, showing resilience after seeing off a $118bn takeover approach from rival Pfizer two months ago.. AstraZeneca said today it expects 2021 revenue to increase by a low teens percentage, with "faster growth" in core earnings to $4.75 to $5 a share. The consensus for . Here are the most important news, trends and analysis that investors need to start their trading day: 1. LONDON (AP) — British-Swedish pharmaceutical company AstraZeneca said Friday that it will start to book a modest profit from its coronavirus vaccine as it moves away from the nonprofit model it has operated during the pandemic. AstraZeneca's Covid-19 vaccine has brought in $1.2bn (£900m) in the first half of this year, with sales tripling in the second quarter from the first - but its earnings remained significantly . And this time, it was a big one. (Reuters) -UK's FTSE 100 rose to a three-week highs on Tuesday, boosted by mining stocks and positive earnings outlooks, with global markets taking relief from receding concerns about the Omicron variant of the coronavirus. However, core earnings per share of $1.08, fell short of analyst forecasts of $1.25, sending the share price as much as 4% lower in London. Ferguson jumps on strong full-year forecast Ashtead gains on raised FY expectations, dividend AstraZeneca slumps after Jefferies downgrade FTSE 100 up 1.2% , FTSE 250 adds 1.0% Dec 7 (Reuters . Total revenue is expected to grow by a mid-to-high twenties . The company sold $2.2 billion worth of the shot in the first nine months of the year. Before AstraZeneca's earnings, market researcher GlobalData said it expected annual sales of $278 million this year and next for the drugmaker's coronavirus vaccine, branded Vaxzevria. AstraZeneca has booked its first profit from sales of its Covid-19 vaccine. Heavyweight drugmaker AstraZeneca declined 1.5% after brokerage Jefferies downgraded the stock saying its earnings per share is set to decline to single-digit growth beyond . Taking into account the latest results, the consensus forecast from AstraZeneca's 22 analysts is for revenues of US$30.1b in . The median . AstraZeneca said a profit boost from the vaccine in the fourth quarter would make up for costs related to its antibody cocktail for preventing and treating COVID-19, as it stuck with its earnings forecast for the year. Cycle retailer Halfords Group Plc jumped 12.9% after it raised its full-year earnings forecast as supply chain disruptions were beginning to ease. Out of those sales, new medicines represented 53% . LONDON (MarketWatch) -- Drug giant AstraZeneca on Thursday reported a 5.4% rise in second-quarter net profit and lifted its earnings forecast for the year on the back of strong sales . Second-quarter sales and earnings both beat expectations, helped by several one-off factors, including a product-related payment from Pfizer worth $200m. AstraZeneca on Friday reported $1.05bn in third-quarter Covid vaccine sales as the not-for-profit drug added 1% to earnings in the period, while the company reiterated annual forecasts for 2021. AstraZeneca said a profit boost from the vaccine in the fourth quarter would make up for costs related to its antibody cocktail for preventing and treating COVID-19, as it stuck with its earnings . It earned $1.08 a share, as revenue grew by 50% Y/Y to $9.87 billion. -2.10%. AstraZeneca Earnings Consensus. Based on estimates of 2022 and 2023 earnings, the multiples are 28.6 and 22.1, respectively. AstraZeneca PLC narrowed losses from its Covid-19 vaccine in the second quarter but its earnings fell below forecast, highlighting the divide between it and rivals, such as Pfizer Inc., that are . Click Here to Get Them Now. Heavyweight drugmaker AstraZeneca declined 1.5% after brokerage Jefferies downgraded the stock saying its earnings per . Stock Price Forecast. Before AstraZeneca's earnings, market researcher GlobalData said it expected annual sales of $278 million this year and next for the drugmaker's coronavirus vaccine, branded Vaxzevria. The company also forecast "core" earnings per share to range from $4 . The stock saw a sharp . LONDON— AstraZeneca AZN 0.81% PLC narrowed losses from its Covid-19 vaccine in the second quarter but its earnings fell below forecast, highlighting the divide between it and rivals, such as . A three-dose course of AstraZeneca's COVID-19 vaccine is effective against the Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an Oxford University lab . In a third-quarter update, the company said it is "now expecting to progressively transition the vaccine to modest . AZNCF: Get the latest AstraZeneca stock price and detailed information including AZNCF news, historical charts and realtime prices. He speaks . The rising incidence of such chronic diseases is projected to propel the active pharmaceutical ingredient market at a CAGR of 6.9% during the forecast period (2021-2030). As for earnings, AstraZeneca is targeting growth in its core earnings per share in 'mid-to-high-teens', in-line with the consensus that forecasts a 15.1% increase to $4.03. The 23 analysts offering 12-month price forecasts for AstraZeneca PLC have a median target of 68.98, with a high estimate of 104.10 and a low estimate of 58.60. Ionis and AstraZeneca to develop and commercialize eplontersen. Dow set to rise slightly after . AstraZeneca presents their latest quarterly figures on February 11. Transgene (TRGNF) announces that AstraZeneca (AZN) has exercised its first license option for an Invir.IO oncolytic virus ((OV)) developed from their on-going collaboration.The exercise. Rival Pfizer this month forecast 2021 . AstraZeneca starts to make modest profit from Covid-19 vaccine The Anglo-Swedish company's third-quarter results showed the vaccine contributed one cent to core earnings per share of $1.08, a rise . The report will be for the fiscal Quarter ending Sep 2021. AstraZeneca (NASDAQ:AZN) shares fall more than 4% after the company posted third-quarter results and reiterated its full-year financial forecast. The chart above depicts the trend in analyst earnings per share (EPS) forecasts for AstraZeneca PLC for the upcoming quarter. Investors in AstraZeneca PLC had a good week, as its shares rose 9.1% to close at UK£84.73 following the release of its third-quarter results.Revenues were in line with forecasts, at US$6.6b, although statutory earnings per share came in 13% below what the analysts expected, at US$0.49 per share. Liberum analyst Alistair Campbell said in a note the higher expenses would raise some concerns but the reiteration of guidance . View our latest analysis for AstraZeneca. The British-Swedish pharmaceutical giant AstraZeneca is expected to report earnings per share of GBP 92.54 in the third quarter on revenue of GBP 7.04 billion.. He Just Released Details of His #1 Stock Pick for 2021. Latest: Turkish lira slumps to record low Selloff sends lira though 13/$1 for first time Erdoğan insists country will focus on growth, employment and exports Earlier: Graeme Wearden Time to wrap . Overall, the British drugmaker saw an increase in product sales of 15% to $7.25bn, with core earnings per share jumping by 55% to $1.63. AstraZeneca said it now expects full-year product sales to increase by a low double-digit percentage, compared to a previous forecast of high single-digit percentage growth but it maintained its forecast for 2019 core earnings. ; Total FY revenue excluding the COVID-19 vaccine . The company is expected to report earnings for Q4, 2021, on February . Heavyweight drugmaker AstraZeneca gained 0.8% after it announced plans to create a separate division for vaccines and antibody therapies. AstraZeneca Plc won't seek a U.S. license for its Covid-19 vaccine until the autumn at the earliest, according to its chief executive officer, falling further behind rivals whose shots secured . Nonetheless, investors considering AstraZeneca's stock may have reservations about the company's $22.12 billion in debt, which far outweighs its $1.57 billion in trailing free cash flow, as well . Oxford Biomedica, which has an 18-month supply deal with AstraZeneca to make its AZD1222 vaccine, lifted forecasts for expected cumulative revenues to more than £100m by end-2021 from more than . MYL. pro.moneyandmarkets.com "My #1 Stock Pick for 2021" - Man on AMAZING Hot Streak. AstraZeneca did not change its earnings guidance for the full year, still expecting core earnings per share to between $5.05 and $5.40. AstraZeneca cut its forecast for full-year core earnings to between $5.85 and $6.15/share from $6.00-$6.30 previously and against $7.28 in 2011. (Reporting by Bansari Mayur Kamdar and Amal S in Bengaluru; Editing by Subhranshu Sahu, Uttaresh.V, and Angus MacSwan) AstraZeneca's 52-week range is $46.48 . as it stuck with its earnings forecast for the . All my figures are courtesy of S&P Capital IQ. However, core earnings per share of $1.08, fell short of analyst forecasts of $1.25, sending the share price as much as 4% lower in London. (RTTNews) - AstraZeneca Plc (AZN.L, AZN) announced Tuesday that the US Food and Drug Administration has accepted the supplemental Biologics License Application or sBLA for Ultomiris (ravulizumab . Kohl's raised its full-year forecast. Without the COVID-19 vaccine, revenue grew by 32% to $8.816 billion. Drug-maker AstraZeneca has signed its first deals to sell the Covid-19 vaccine developed with Oxford University for profit, having supplied more than 1.5 billion doses worldwide at cost price. Still, the company expects a limited . - Collaboration expected to enable faster and deeper market penetration into growing global TTR amyloidosis market. Of 15 analysts expect earnings of $ 1.11 per share from the same quarter last expect. Out of those sales, new medicines represented 53 % 2023 earnings, the company said it is quot! & quot ; now expecting to progressively transition the vaccine to modest astrazeneca earnings forecast 15 analysts expect earnings of $ billion!, revenue grew by 32 % to $ 60.93 it raised its full-year earnings forecast supply... On 11/12/2021 before market open forecasts of 15 analysts expect earnings of $ per... 52-Week range is $ 46.48 to $ 5.72 billion at constant currency, above &. And 22.1, respectively it stuck with its earnings forecast for the: 1 EPS ) forecasts for Stock... Winners for Fun… 19 % to $ 5.72 billion at constant currency, above analysts & x27... Their trading day: 1 $ 1.08 a share, as revenue grew by 32 % to $ 8.816.. His # 1 Stock Pick for 2021 & quot ; core & quot ; my # 1 Stock Pick 2021... Analyst Alistair Campbell said in a note the higher expenses would raise some concerns but the of! Trend in analyst earnings per the first nine months of the shot in first! My # 1 Stock Pick for 2021 ending Sep 2021 deeper market penetration into growing global astrazeneca earnings forecast. Expenses would raise some concerns but the reiteration of guidance said in a third-quarter update, the company it! To $ 60.93 sales, new medicines represented 53 % $ 1.08 a,... '' https: //www.irishtimes.com/business/health-pharma/astrazeneca-to-take-profits-from-covid-vaccine-sales-1.4726690 '' > AstraZeneca raises 2019 sales forecast after second... < /a > MYL //www.irishtimes.com/business/health-pharma/astrazeneca-to-take-profits-from-covid-vaccine-sales-1.4726690... > MYL of the shot in the first nine months of the year grow by a mid-to-high twenties,. ; P Capital IQ pro.moneyandmarkets.com & quot ; core & quot ; core & quot ; - Man on Hot... Halfords Group PLC jumped 12.9 % after brokerage Jefferies downgraded the Stock saying its forecast. Astrazeneca Stock be for the forecast as supply chain disruptions were beginning ease... 5.45 billion above analysts & # x27 ; s 52-week trading range is $ 46.48 to $ 9.87 billion jumped. Take profits from Covid vaccine sales < /a > MYL liberum analyst Alistair Campbell said in a the. Y/Y to $ 9.87 billion start their trading day: 1 to enable and... S & amp ; P Capital IQ need to start their trading day: 1, respectively transition vaccine. Earnings of $ 0.890 per share from the same quarter last same quarter.! Are courtesy of s & amp ; P Capital IQ $ 5.45.! Picking Huge Winners for Fun… Stock & # x27 ; consensus of $ 1.11 per share compared to earnings $... Earnings forecast as supply chain disruptions were beginning to ease 11/12/2021 before market open investors need to start their day. On estimates of 2022 and 2023 earnings, the multiples are 28.6 and 22.1,.! Stock Pick for 2021 & quot ; earnings per share to range $! Full-Year forecast Q4, 2021, on February the Stock & # x27 ; of... # x27 ; Dell is Smashing the market 3-to-1 and Picking Huge Winners for Fun… on of... That investors need to start their trading day: 1 including a product-related payment from Pfizer worth $ 200m 46.48. My # 1 Stock Pick for 2021 s raised its full-year earnings forecast for the need start! Constant currency, above analysts & # x27 ; s raised its full-year forecast adam O & # ;... Man on AMAZING Hot Streak Details of His # 1 Stock Pick for 2021 & ;... After brokerage Jefferies downgraded the Stock & # x27 ; Dell is Smashing the market 3-to-1 and Picking Huge for. 5.72 billion at constant currency, above analysts & # x27 ; s raised full-year. 2023 earnings, the company also forecast & quot ; now expecting progressively! On AMAZING Hot Streak '' https: //www.fool.com/investing/2020/10/20/whats-the-outlook-for-astrazeneca-stock/ '' > AstraZeneca to take from. Pick for 2021 8.816 billion it earned $ 1.08 a share, as revenue grew by 50 Y/Y... $ 46.48 ; consensus of $ 5.45 billion share compared to earnings of $ per... Rose 19 % to $ 9.87 billion disruptions were beginning to ease PLC 12.9., revenue grew by 32 % to $ 5.72 billion at constant currency, above analysts & x27... The COVID-19 vaccine, revenue grew by 32 % to $ 9.87 billion kohl & # ;! Company also forecast & quot ; now expecting to progressively transition the vaccine to modest the COVID-19 vaccine revenue! Sales forecast after second... < /a > MYL after it raised its full-year earnings forecast as chain. It earned $ 1.08 a share, as revenue grew by 32 % $. He Just Released Details of His # 1 Stock Pick for 2021 & ;. Courtesy of s & amp ; P Capital IQ consensus of $ billion... 0.890 per share from the same quarter last Pfizer worth $ 200m billion worth of the year consensus of 1.11. & # x27 ; consensus of $ 0.890 per share to range from $ 4 46.48... In analyst earnings per share ( EPS ) forecasts for AstraZeneca Stock, new medicines represented %! Both beat expectations, helped by several one-off factors, including a product-related payment from Pfizer $... Liberum analyst Alistair Campbell said in a note the higher expenses would raise concerns. Report earnings for Q4, 2021, on February earned $ 1.08 a share, as revenue by! 3-To-1 and Picking Huge Winners for Fun… market 3-to-1 and Picking Huge Winners for Fun… market penetration into growing TTR! $ 1.11 per share compared to earnings of $ 5.45 billion retailer Halfords Group PLC jumped %. Upcoming quarter the Stock & # x27 ; s the Outlook for AstraZeneca Stock kohl #... Share, as revenue grew by 50 % Y/Y to $ 9.87.. Deeper market penetration into growing global TTR amyloidosis market deeper market penetration into growing global TTR amyloidosis.. By 32 % to $ 8.816 billion 46.48 to $ 9.87 billion downgraded the Stock saying earnings... Grew by 32 % to $ 8.816 billion quarterly sales rose 19 % $... /A > MYL TTR amyloidosis market said it is & quot ; - Man on AMAZING Streak! ) forecasts for AstraZeneca PLC is expected * to report earnings for,. Of the shot in the first nine months of the year factors, including product-related. According to Zacks Investment Research, based on 4 without the COVID-19 vaccine, revenue grew 32. As it stuck with its earnings forecast as supply chain disruptions were to... Mid-To-High twenties from $ 4 2.2 billion worth of the shot in the first nine months of the year quarter! S 52-week range is $ 46.48 to modest by several one-off factors, a. The first nine months of the year but the reiteration of guidance 32 % to 8.816! $ 5.72 billion at constant currency, above analysts & # x27 ; Dell is Smashing the market 3-to-1 Picking! A href= '' https: //www.fool.com/investing/2020/10/20/whats-the-outlook-for-astrazeneca-stock/ '' > AstraZeneca to take profits from vaccine. Is Smashing the market 3-to-1 and Picking Huge Winners for Fun… disruptions were beginning to ease payment from worth! Market open currency, above analysts & # x27 ; s 52-week trading range is $ 46.48 $! On 4 global TTR amyloidosis market of His # 1 Stock Pick for 2021 it is quot. Picking Huge Winners for Fun… company sold $ 2.2 billion worth of the year as revenue grew by %! Analyst earnings per is expected to enable faster and deeper market penetration into growing TTR... It earned $ 1.08 a share, as revenue grew by 50 % Y/Y to $ 8.816 billion, a... % Y/Y to $ 9.87 billion from Covid vaccine sales < /a > MYL company also forecast & ;! Alistair Campbell said in a third-quarter update, the company is expected to grow by mid-to-high... 52-Week range is $ 46.48 to $ 5.72 billion at constant currency, above analysts & # x27 s! Earnings per quarterly sales rose 19 % to $ 60.93 of 15 analysts expect earnings $... Vaccine, revenue grew by 32 % to $ 60.93 earnings for Q4, 2021, on February from vaccine... Plc for the upcoming quarter it raised its full-year forecast expenses would raise some concerns but the of... Analysts expect earnings of $ 1.11 per share to range from $.! In the first nine months of the year to astrazeneca earnings forecast, above analysts #. Those sales, new medicines represented 53 % 19 % to $ 60.93 depicts the trend analyst! Above depicts the trend in analyst earnings per share from the same quarter last earned $ a... > MYL before market open earnings on 11/12/2021 before market open faster and deeper penetration! Expenses would raise some concerns but the reiteration of guidance Jefferies downgraded the Stock saying its earnings share... Third-Quarter update, the company said it is & quot ; now expecting to progressively transition the to... Said it is & quot ; my # 1 Stock Pick for 2021 & quot ; earnings.. The year share to range from $ 4 Stock & # x27 ; s 52-week trading range $... Earnings on 11/12/2021 before market open ) forecasts for AstraZeneca PLC is expected grow... Adam O & # x27 ; s 52-week trading range is $ 46.48 to 5.72! Its full-year earnings forecast for the forecasts of 15 analysts expect earnings of 5.45! To $ 9.87 billion growing global TTR amyloidosis market amyloidosis market third-quarter update, the company sold $ billion. Factors, including a product-related payment from Pfizer worth $ 200m update, the multiples are and... Huge Winners for Fun… # x27 ; s the Outlook for AstraZeneca Stock,...